TNF and inflammatory bowel disease: On the other hand, the use of immunomodulators (15.2%) and anti-TNF agents (12.7%) was greater in our patients than in those of Juneja et al., where immunomodulators were used by just 6% of the older patients with IBD and anti-TNF agents by 9% and 1% of older patients with CD and UC, respectively [29].